CN1436854A - 人角质细胞生长因子-2的生产方法 - Google Patents
人角质细胞生长因子-2的生产方法 Download PDFInfo
- Publication number
- CN1436854A CN1436854A CN 02110808 CN02110808A CN1436854A CN 1436854 A CN1436854 A CN 1436854A CN 02110808 CN02110808 CN 02110808 CN 02110808 A CN02110808 A CN 02110808A CN 1436854 A CN1436854 A CN 1436854A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- expression vector
- kgf
- keratinocyte growth
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282414 Homo sapiens Species 0.000 title abstract description 13
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 230000010261 cell growth Effects 0.000 title abstract description 9
- 239000013604 expression vector Substances 0.000 claims abstract description 24
- 238000000746 purification Methods 0.000 claims abstract description 8
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims description 16
- 102000057239 human FGF7 Human genes 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 14
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 238000005277 cation exchange chromatography Methods 0.000 claims description 6
- 238000011097 chromatography purification Methods 0.000 claims description 6
- 238000005227 gel permeation chromatography Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 4
- 238000005571 anion exchange chromatography Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003102 growth factor Substances 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 230000006378 damage Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 6
- 206010028116 Mucosal inflammation Diseases 0.000 description 6
- 201000010927 Mucositis Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 208000004210 Pressure Ulcer Diseases 0.000 description 5
- 230000009693 chronic damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 108010077805 Bacterial Proteins Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- SOIAHPSKKUYREP-CIUDSAMLSA-N Gln-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N SOIAHPSKKUYREP-CIUDSAMLSA-N 0.000 description 2
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 2
- JPXNYFOHTHSREU-UWVGGRQHSA-N Gly-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN JPXNYFOHTHSREU-UWVGGRQHSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 2
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 2
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 2
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 102220369446 c.1274G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 102220023257 rs387907546 Human genes 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- -1 KGF-1 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000037998 chronic venous disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229950004205 repifermin Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
成分 | 1 | 2 | 3 | 4 | 5 | 6 |
胰蛋白胨 | 16 | 10 | 5 | 16 | 10 | |
酵母提取物 | 5 | 10 | 5 | 10 | 10 | 2 |
K2HPO4 | 7 | 2 | 5 | |||
KH2PO4 | 8 | 1 | 3 | 2.7 | ||
Na2HPO4 | 2.5 | 6 | 28.6 | |||
(NH4)2SO4 | 5 | 0.6 | ||||
MgSO4·7H2O | 2 | 1 | 2.5 | 2mM | ||
葡萄糖 | 5 | 5 | 2 | 10 | ||
NH4Cl | 0.1 | 0.7 | ||||
NaCl | 5 | 0.5 | 5 | |||
柠檬酸钠 | 1.7 | |||||
pH | 7.0 |
方法一 | 方法二 | |
KGF-2表达水平(占全菌蛋白比例) | 18% | 7.2% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02110808 CN1247794C (zh) | 2002-02-08 | 2002-02-08 | 人角质细胞生长因子-2的生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02110808 CN1247794C (zh) | 2002-02-08 | 2002-02-08 | 人角质细胞生长因子-2的生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1436854A true CN1436854A (zh) | 2003-08-20 |
CN1247794C CN1247794C (zh) | 2006-03-29 |
Family
ID=27628290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02110808 Expired - Lifetime CN1247794C (zh) | 2002-02-08 | 2002-02-08 | 人角质细胞生长因子-2的生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1247794C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105925647A (zh) * | 2016-06-24 | 2016-09-07 | 成都远睿生物技术有限公司 | 一种重组人角质细胞生长因子-2工程菌的发酵方法及发酵培养基 |
CN106676121A (zh) * | 2017-01-25 | 2017-05-17 | 江苏易肌雪生物科技股份有限公司 | 一种简便制备活性人kgf‑2d31的方法 |
CN108686201A (zh) * | 2018-06-29 | 2018-10-23 | 上海新生源医药集团有限公司 | 用于治疗口腔黏膜炎的kgf-2及其制剂 |
CN115282260A (zh) * | 2021-12-24 | 2022-11-04 | 温州医科大学 | Kgf-2制备治疗皮肤功能障碍药物中的应用 |
-
2002
- 2002-02-08 CN CN 02110808 patent/CN1247794C/zh not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105925647A (zh) * | 2016-06-24 | 2016-09-07 | 成都远睿生物技术有限公司 | 一种重组人角质细胞生长因子-2工程菌的发酵方法及发酵培养基 |
CN106676121A (zh) * | 2017-01-25 | 2017-05-17 | 江苏易肌雪生物科技股份有限公司 | 一种简便制备活性人kgf‑2d31的方法 |
CN108686201A (zh) * | 2018-06-29 | 2018-10-23 | 上海新生源医药集团有限公司 | 用于治疗口腔黏膜炎的kgf-2及其制剂 |
CN115282260A (zh) * | 2021-12-24 | 2022-11-04 | 温州医科大学 | Kgf-2制备治疗皮肤功能障碍药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1247794C (zh) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1062182C (zh) | 生理活性物质 | |
WO2006015214A3 (en) | Umbilical cord stem cell composition & method of treating neurological diseases | |
JPH05502443A (ja) | 幹細胞の成長阻害法 | |
CN100451034C (zh) | 猪γ干扰素及其编码基因与应用 | |
EA019305B1 (ru) | Способ получения плюрипотентных стволовых клеток взрослого организма из крови, в частности периферической, и применение полученных клеток в области медицины | |
CN1763093A (zh) | 含有hiv转导结构域的生存素突变体及制备方法和应用 | |
CN101402688B (zh) | 一种融合蛋白及其编码基因与应用 | |
CN100484959C (zh) | 一种改良重组猪α干扰素蛋白及其编码基因与应用 | |
CN1436854A (zh) | 人角质细胞生长因子-2的生产方法 | |
CN101508992A (zh) | 三疣梭子蟹抗菌肽基因及其克隆方法 | |
CN1228995A (zh) | 一种治疗老年性痴呆症、帕金森症、心脑血管病的药物 | |
CN106552259A (zh) | 一种融合蛋白及其治疗疾病的用途 | |
CN102241776B (zh) | Rankl-tnf样区融合蛋白及其制备方法和应用 | |
CN1125081C (zh) | 重组天然和新型人胰岛素及其制备方法 | |
CN1207305C (zh) | 一种重组人白细胞介素-11的制备方法 | |
CN114031672A (zh) | 一种多肽及其在制备软骨修复和/或骨关节炎药物中的应用 | |
CN1323715C (zh) | c-ski基因及其多肽在制备促进组织修复及减轻瘢痕形成药物中的应用 | |
CN101041691A (zh) | 中国南海信号芋螺神经毒素基因lt5.4及其应用 | |
CN101897953A (zh) | 无创性高穿透性表皮生长因子及其应用 | |
CN100535005C (zh) | 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法 | |
CN101182529A (zh) | 一种融合基因以及基因工程菌及其制备和应用 | |
CN1259337C (zh) | 人甲状旁腺激素基因突变体合成、表达、制备及应用 | |
CN1781943A (zh) | 中国南海信号芋螺神经毒素及其编码序列和用途 | |
CN113384579B (zh) | 一种药物组合物及其在延缓衰老中的应用 | |
CN1232532C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI URBAN NEWSUMMIT BIOPHARMA CO., LTD. Free format text: FORMER OWNER: SHANGHAI XINSHENGYUAN MEDICINE RESEARCH CO., LTD. Effective date: 20100907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200233 TOWER A, 4/F, NO.398, TIANLIN ROAD, SHANGHAI TO: 202174 YIQIU COMPLEX BUILDING, NEIGHBOREHOOD 5, CHANGZHENG FARM, CHONGMING COUNTY, SHANGHAI |
|
CP01 | Change in the name or title of a patent holder |
Address after: 200233, Tianlin Road, Shanghai, No. 398, 4, block A Patentee after: Shanghai Newsummit Biopharma Co.,Ltd. Address before: 200233, Tianlin Road, Shanghai, No. 398, 4, block A Patentee before: SHANGHAI XINSHENGYUAN MEDICINE RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100907 Address after: 202174 Shanghai Chongming County Long March Farm 5 neighborhood 1 Qiu complex Patentee after: Shanghai city xinshengyuan Pharmaceutical Co.,Ltd. Address before: 200233, Tianlin Road, Shanghai, No. 398, 4, block A Patentee before: Shanghai Newsummit Biopharma Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: WUHAN GUANGGU NEWSUMMIT BIO-PHARMACEUTICAL CO., LT Free format text: FORMER NAME: SHANGHAI NEWSUMMIT PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 430000, Hubei Wuhan New Technology Development Zone, East Lake Hi Road bio pharmaceutical park small and medium-sized enterprise Park Service Center (building A-7) Patentee after: Wuhan Optics Valley xinshengyuan Biological Pharmaceutical Co.,Ltd. Address before: 202174 Shanghai Chongming County Long March Farm 5 neighborhood 1 Qiu complex Patentee before: Shanghai city xinshengyuan Pharmaceutical Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ANHUI XINHUAKUN BIOLOGICAL ENGINEERING CO., LTD. Free format text: FORMER OWNER: WUHAN GUANGGU NEWSUMMIT BIO-PHARMACEUTICAL CO., LTD. Effective date: 20140530 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430000 WUHAN, HUBEI PROVINCE TO: 230000 HEFEI, ANHUI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140530 Address after: High tech Zone Customs Road Hefei city Anhui province 230000 No. 9 biotechnology A Building Room 601 Patentee after: ANHUI XINHUAKUN BIOENGINEERING Co.,Ltd. Address before: 430000, Hubei Wuhan New Technology Development Zone, East Lake Hi Road bio pharmaceutical park small and medium-sized enterprise Park Service Center (building A-7) Patentee before: Wuhan Optics Valley xinshengyuan Biological Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180822 Address after: 325600 Yueqing City, Zhejiang Province, Hongqiao Town South Village, Yueqing City Science and Technology Incubation and Entrepreneurship Service Center, Life and Health Industrial Park, a comprehensive office building, 8th floor A Patentee after: Zhejiang thirty thousand Pharmaceutical Co.,Ltd. Address before: 230000 Room 601, Anke bio A, 9 Customs Road, hi tech Zone, Hefei, Anhui. Patentee before: ANHUI XINHUAKUN BIOENGINEERING Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190116 Address after: 430000 Room 536, Block B1, Biological Innovation Park, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Guanggu Asia-Pacific Pharmaceutical Co.,Ltd. Address before: 325600 Yueqing City, Zhejiang Province, Hongqiao Town South Village, Yueqing City Science and Technology Incubation and Entrepreneurship Service Center, Life and Health Industrial Park, a comprehensive office building, 8th floor A Patentee before: Zhejiang thirty thousand Pharmaceutical Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060329 |